{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-079586","form_type":"8-K","ticker":"ORMP","cik":"0001176309","company_name":"ORAMED PHARMACEUTICALS INC.","filed_at":"2023-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.316586+00:00","generated_at":"2026-06-10T08:32:22.819373+00:00","sec_items":["1.01","1.02","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Oramed receives $101.875M senior secured note from Scilex with warrants for 17M shares","bullets":["Principal $101,875,000, 18-month maturity, interest SOFR+8.5% (4% floor), paid in kind.","Oramed gets penny warrants for 13M shares at $0.01 (vesting conditions) and 4M transferred warrants at $11.50.","Note is senior secured on substantially all assets of Scilex and subsidiaries with first-priority lien.","Prior Sorrento SPA and DIP loan terminated; Scilex assumes DIP, buys Sorrento's Scilex equity for $110M.","Oramed receives $2.91M expense reimbursement and right to designate a board observer."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-079586","json":"https://secwatch.observer/filing/0001213900-23-079586.json","markdown":"https://secwatch.observer/filing/0001213900-23-079586.md","text":"https://secwatch.observer/filing/0001213900-23-079586.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1176309/000121390023079586/0001213900-23-079586-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1176309/000121390023079586/ea185680-8k_oramedpharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T08:32:22.819373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3e13dabd1db011b6baaac6e09abd687cb78b84a0","claim":"ORAMED PHARMACEUTICALS INC. entered into Securities Purchase Agreement with Scilex Holding Company (effective 2023-09-21).","evidence_excerpt":"On September 21, 2023 (the “Closing Date”), the Company entered into, and consummated the transactions contemplated by, a Securities Purchase Agreement (the “Scilex SPA”) with Scilex and the Agent (as defined below).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390023079586/0001213900-23-079586-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Scilex Holding Company"},{"label":"Effective","value":"2023-09-21"}],"fact_type":"material_agreement"},{"claim_id":"437d24eaaeb230c836e9c6fe599437f14702ebd6","claim":"ORAMED PHARMACEUTICALS INC. entered into Senior Secured Promissory Note with Scilex Holding Company valued at $101,875,000 (effective 2023-09-21).","evidence_excerpt":"a Senior Secured Promissory Note due 18 months from the date of issuance in the principal amount of $101,875,000 (the “Note”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390023079586/0001213900-23-079586-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"Scilex Holding Company"},{"label":"Value","value":"$101,875,000"},{"label":"Effective","value":"2023-09-21"}],"fact_type":"material_agreement"},{"claim_id":"b1e60ffeeb56a5a61f100b78b293bc3be9c38853","claim":"ORAMED PHARMACEUTICALS INC. terminated Stock Purchase Agreement with Sorrento Therapeutics, Inc. (effective 2023-09-21).","evidence_excerpt":"ugust 7, 2023, Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), entered into a Stock Purchase Agreement (as subsequently amended on August 9, 2023 and August 21, 2023, the “Sorrento SPA”) with Sorrento Therapeutics, Inc.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1176309/000121390023079586/0001213900-23-079586-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Sorrento Therapeutics, Inc."},{"label":"Effective","value":"2023-09-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}